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Abstract
The somatotropic axis is intricately involved in normal sleep, as evidenced by the fact that 
hypothalamic growth hormone-releasing hormone (GHRH) has sleep promoting effects and 
pituitary growth hormone (GH) release is strongly associated with slow-wave sleep (SWS). 
Abnormalities in the somatotropic axis, such as GH deficiency of hypothalamic or pituitary origin, 
result in an alteration of normal sleep patterns which may explain the fatigue reported in these 
individuals. Sleep disorders such as narcolepsy, in which individuals abnormally enter rapid eye 
movement (REM) sleep at sleep onset are also associated with an altered GHRH circadian rhythm 
and abnormal GH secretion. While few studies are available, this review explores what is known 
about sleep abnormalities in GH deficiency, the effect of treatment on sleep in patients with GH 
deficiency, and GH secretion in narcolepsy. Emerging evidence suggests a hypothalamic link 
between narcolepsy and GH secretion. We also describe the unique constellation of isolated 
idiopathic GH deficiency and severe excessive sleepiness in adopted Nicaraguan siblings, one of 
which has narcolepsy and the other idiopathic hypersomnia.
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Background: Somatotropic Axis and Sleep
Normal sleep consists of two stages: REM and non-REM sleep which alternate cyclically 
(1). Non-REM sleep consists of stages 1, 2, 3, and 4, each of which has its own unique brain 
activity (2). Stages 3 and 4, which predominantly happen during the first third of nightly 
sleep, are known as SWS and are considered the deep stages of sleep (3). Non-REM begins 
first, progresses through its stages, and subsequently REM sleep occurs (1).
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It is well known that pituitary GH is secreted in a pulsatile fashion primarily during sleep 
and reaches its highest amplitude during SWS (4–6). This release occurs secondary to 
stimulation by hypothalamic GHRH which results in significantly increased GH secretion 
(7). GHRH given during SWS, as opposed to during REM sleep or an awakened state, 
results in a larger GH response (8). GHRH itself has sleep promoting effects (9) and in 
healthy young adult males its episodic rather than continuous administration increases SWS 
duration (7, 10). In the rodent model, this sleep promoting effect has been shown to occur 
independent of GH (11). While GHRH’s effect on GH release and promotion of SWS occur 
through distinct hypothalamic neurons, these processes are not completely independent, but 
instead are quite interconnected (12, 13).
Some have hypothesized that in pituitary GH deficiency, the lack of negative feedback 
inhibition of GH on GHRH leads to increased activity of GHRH and the subsequent 
promotion of excessive SWS (14). In contrast, patients with a hypothalamic origin may have 
deficient SWS and REM sleep due to the combination of GHRH and GH deficiencies (15).
Indeed, subjects with isolated GH deficiency have been shown to have decreased duration of 
SWS (16) and REM sleep (17) which corrects with appropriate GH replacement (18, 19). In 
a study with 18 healthy young adults, GH administration decreased SWS, but increased 
REM sleep (20).
These studies suggest that since the somatotropic axis is intricately involved in normal sleep, 
abnormalities may contribute to the fatigue reported in individuals with GH deficiency (21, 
22). With the paucity of data, further studies are needed to clarify this potential relationship.
Case Report
An 8 4/12 year old Hispanic boy and his 6 6/12 year old sister were referred for pediatric 
endocrinology evaluation due to poor growth. Both had been adopted from a Nicaraguan 
orphanage 2 years earlier where they had been placed due to emotional and physical neglect. 
Both had a history of severe malnutrition which had resolved by the time of our evaluation. 
Additional history consisted of debilitating fatigue and a pattern of sleeping ~18 hours a day, 
rendering it impossible for them to attend school or have a normal life.
On physical exam, heights were at −2.17 SD (boy) and −3.25 SD (girl) with BMIs at −1.38 
SD (boy) and −1.04 SD (girl). Evaluation revealed low serum IGF-1 levels of 20 ng/ml and 
15 ng/ml and stimulation testing demonstrated peak GH levels of 2.39 ng/dl and 4.31 ng/dl 
in the boy and girl, respectively. Pituitary MRIs were normal. Bone age xrays were delayed 
at ~−3 SD in the boy and −4 SD in the girl. Thyroid function tests and AM cortisol were 
normal. GH therapy was started at 0.3 mg/kg/wk and growth velocity improved from 0 to 
7.92 cm/yr (boy), and from 2 to 5.56 cm/yr (girl) during the first 6 months of therapy. IGF-1 
levels normalized in both.
Both entered puberty spontaneously at age 11 11/12 years (boy) and 10 8/12 years (girl). GH 
therapy was weight-adjusted and most recent growth parameters have improved with height 
−1.33 SD, BMI of −0.12 SD, growth velocity of 11.2 cm/yr, and bone age consistent with 
chronological age at −0.25 SD in the boy and height −1.02 SD, BMI of −0.05 SD, growth 
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velocity of 14.8 cm/yr, and a delayed bone age of −3SD in the girl. The children’s growth 
charts are shown in Figure 1.
While on GH therapy, the mother reported worsening hypersomnia prompting referral to 
sleep medicine where the boy was diagnosed with narcolepsy and the girl with idiopathic 
hypersomnia. Both were started on modafinil, transitioned to armodafinil, and finally 
sodium oxybate due to poor response. With this most recent regimen, their excessive 
sleepiness has improved.
Genetic testing has been inconclusive. Whole exome sequencing revealed a previously 
unreported variant in one of two copies of the CPA1 gene (c.497 G>T (p.G166V)) of 
uncertain significance in both siblings. Other variants in this gene have been associated with 
pancreatic disease, but there is no evidence of pancreatic issues in these siblings. 
Mitochondrial DNA sequencing and metabolic evaluation were negative. Interestingly, 
testing did reveal that they are half-siblings.
Discussion
Sleep Abnormalities in GH deficiency
There are few human studies that have examined sleep quality in individuals with GH 
deficiency. In one, 30 untreated adult subjects with GH deficiency were compared to 30 
matched controls (14). Compared with controls, subjects with GH deficiency had poorer 
sleep quality determined by the Pittsburgh Sleep Quality Index and also had lower quality of 
life scores. Those with pituitary GH deficiency had a longer duration and more intense SWS, 
while those with hypothalamic GH deficiency had lower intensity SWS. A sleep study using 
wrist actigraphy and polysomnography in 9 adults with GH deficiency showed decreased 
sleep duration and increased sleep fragmentation compared to 9 healthy controls (13). 
Children with GH deficiency also have different sleep characteristics. In a study of 10 
children with GH deficiency compared with 20 matched controls, those with GH deficiency 
had abnormal sleep macrostructure (decreased sleep duration, sleep efficiency, movement 
time, stage 2 non-REM sleep, and percent REM sleep) and altered sleep microstructure 
(reduced arousal instability) (23).
Effect of Treatment on Sleep in GH Deficiency
In 13 adults with GH deficiency of confirmed or likely pituitary origin, after 4 months of GH 
replacement therapy, there was a significant decrease in sleep duration primarily due to 
decreased SWS intensity and an earlier wake time (24). Several had panhypopituitarism with 
and without surgery or radiotherapy and etiologies of GH deficiency varied among subjects 
and included idiopathic, as well as organic causes. A significant decrease in stage 3 of SWS 
was also seen after GH therapy in 6 of 7 children with GH deficiency (25). Five of these 
children had idiopathic, isolated GH deficiency, one had septo-optic dysplasia, and one 
developed hypopituitarism after resection and radiation therapy for craniopharyngioma. 
Both of these studies suggest that GH replacement deceases SWS, adding support for the 
hypothesis that in pituitary GH deficiency, lack of negative feedback of GH results in 
unopposed GHRH with consequent SWS excess.
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However, other studies have found no difference in sleep in treated subjects with GH 
deficiency (26, 27). In a randomized double-blinded placebo controlled trial over 6 months, 
day and nighttime sleep EEG recordings and a multiple sleep latency test were performed at 
baseline and after 6 months of GH therapy in 17 adults with GH deficiency and no sleep 
effect of therapy was found (26). The etiology in the majority of subjects was a pituitary 
adenoma with subsequent pituitary surgery and occasionally radiation therapy. Thus, it is 
difficult to draw clear conclusions regarding the impact of GH treatment on sleep.
Narcolepsy and Growth Hormone Secretion
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, abnormal 
REM sleep including episodes with loss of muscle tone (cataplexy), sleep paralysis, and 
hypnagogic hallucinations (28). Type 1 narcolepsy is defined by cataplexy and results from 
extensive loss of the hypothalamic neurons that secrete the neurotransmitter hypocretin (also 
known as orexin) (29–31). Type 2 lacks cataplexy and the cause is unknown (28). While 
non-REM sleep normally occurs first, those with narcolepsy enter directly into REM sleep at 
sleep onset (32). Idiopathic hypersomnia is considered a diagnosis of exclusion once other 
causes of excessive daytime sleepiness have been ruled out (33). Features of idiopathic 
hypersomnia include extreme fatigue after awakening from sleep, high sleep efficiency (time 
spent in bed asleep), and shortened sleep latency (length of time from awakened state to 
sleep onset) (33, 34).
While the presence of GH deficiency in narcolepsy has not been investigated, there are a few 
small studies that have explored 24-hour GH secretion in this condition. In 4 adult subjects 
with narcolepsy, the GH peak during SWS was absent or greatly decreased (35) compared 
with the substantial GH peak within 60 minutes of sleep onset that was observed in 4 healthy 
controls. Other studies have demonstrated that people with narcolepsy do not have deficient, 
but rather dysregulated GH secretion that is not clearly linked with sleep stages (36). GH 
secretion and sleep patterns were assessed over 24 hours in 7 adult individuals with 
narcolepsy with confirmed hypocretin deficiency and compared to matched controls (37). 
Basal and pulsatile GH secretion and GHRH-induced GH secretion were similar between 
subjects with narcolepsy and controls, but those with narcolepsy secreted about 50% of their 
total daily GH during the day vs only 25% in the controls.
Short stature and GH deficiency are not known features of narcolepsy. One study has 
described anthropometric and endocrine data in 72 pediatric subjects with type 1 narcolepsy 
over a 1-year follow up period (38). In the 39 subjects who underwent GH stimulation 
testing with arginine and clondinine, 23 had a blunted GH concentration defined by a peak 
level below 8 ng/mL on at least one of the two provocative tests. All had normal IGF-1 z-
scores and all children were of normal height (mean z-score 0.72 +/− 1.07) and appropriate 
for their genetic potential, suggesting a normal functioning GH axis. Growth velocity was 
low only in the subgroup close to completion of puberty which is expected for this pubertal 
stage. While linear growth appears normal, other endocrinopathies that have been reported 
in the setting of narcolepsy are precocious puberty and obesity (38, 39).
Table 1 summarizes features of the somatotropic axis as it relates to GH deficiency, 
narcolepsy, and the normal state.
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While there appears to be a link between abnormalities in the somatotropic axis and sleep 
regulation, evidence supporting a hypothalamic link between narcolepsy and GH deficiency 
is beginning to emerge. The hypocretin, orexin-A, was shown in rat models of GH 
deficiency (hypophysectomized and Lewis dwarf rat) to decrease GHRH expression in the 
paraventricular nuclei (40). Another study using adult male rats demonstrated that 
administration of orexin-A decreased spontaneous GH secretion (41). Hypothalamic 
somatostatin is well-known to inhibit GH release as part of normal physiology (42) and 
orexin-A stimulated somatostatin release in male rats (43). These studies may explain the 
disrupted circadian rhythm of GHRH (37) and abnormal GH secretion in humans with 
narcolepsy (35, 44). Considering the complexity of the GH system, additional cross-
connections involving hypocretins or other modulators of the somatotropic axis likely exist.
Conclusion
To the best of our knowledge, our siblings represent the first report of GH deficiency in the 
setting of narcolepsy and idiopathic hypersomnia. We propose that hypothalamic 
dysfunction may be the link between GH deficiency and sleep disorders in these children. It 
is unclear why the siblings developed increased sleepiness following initiation of GH 
therapy as existing reports have found no effect or an improvement in sleep in subjects 
receiving GH treatment, albeit none of these studies included cases of narcolepsy or 
idiopathic hypersomnia. Further studies, particularly in humans are needed to clarify the 
relationship between GH, narcolepsy, and sleep disorders.
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Growth charts for boy (left) and girl (right). Δ indicates bone ages.
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Table 1.
Established and proposed relationships between the somatotropic axis and sleep in normal physiology, GH 
deficiency, and narcolepsy.
Normal Sleep GH Deficiency Narcolepsy
• GHRH increases 
SWS duration
• GH primarily 
secreted during 
SWS (Stages 3 & 
4)
• Hypothalamic origin
– Deficient SWS and REM 
sleep
• Pituitary origin
– Lack of negative 
feedback of GH on 
GHRH → increased 
GHRH → promotion of 
SWS
• GH peak during SWS absent or 
decreased
• 24-hour secretion not deficient
– Not clearly linked with 
sleep stages
– Greater percentage of 
secretion during daytime 
than controls
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